The invention relates to medicine, in particular to hepatology and virology, and can be used for treating, even until the absolute recovery, patients suffering from viral hepatitis C, including the chronic form thereof. Said invention provides an agent for treating viral hepatitis C in the form of a monomeric lactoferrin apoprotein. The invention also relates to a pharmaceutical composition for treating viral hepatitis C which contains the effective amount of monomeric lactoferrin apoprotein and a pharmaceutically acceptable carrier, filler or excipient. The invention also relates to a method for treating viral hepatitis C, consisting in administering the monomeric lactoferrin apoprotein, and to the use of said monomeric lactoferrin apoprotein for producing a medicinal agent for treating viral hepatitis C. The inventive method makes it possible to totally prevent viremia during two-three week treatment, to prevent viral hepatitis C-infected hepatocytes from being destroyed associated with the emission of additional viruses to the blood system and to bring to the end the existence of apoptosis virus-infected hepatocytes, thereby preventing the development of hepatosis, cirrhosis and oncological liver infection which are the terminal stage of the main disease development.
